ChemoCentryx, Inc. (CCXI)
| Previous Close | 14.78 |
| Open | 14.81 |
| Bid | 15.10 x 1200 |
| Ask | 15.12 x 900 |
| Day's Range | 14.80 - 15.24 |
| 52 Week Range | 9.53 - 70.29 |
| Volume | 528,075 |
| Avg. Volume | 4,559,787 |
| Market Cap | 1.054B |
| Beta (5Y Monthly) | 1.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Aug. 09, 2021 - Aug. 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.29 |
- GlobeNewswire
ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021
MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2021 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (Interna
- Motley Fool
2 Beaten-Down Biotech Stocks That Could Bounce Back
The market hasn't been kind to these two drugmakers, but both have a chance to turn things around.
- Motley Fool
Is Now the Time to Buy ChemoCentryx Stock?
Shares of the highly popular biotech stock ChemoCentryx (NASDAQ: CCXI) ticked up a few notches after a Wall Street analyst upgraded the stock to buy. Stifel analyst Dae Gon Ha thinks a recent development regarding the clinical-stage biotech's lead candidate is a pretty big deal that the rest of the stock market has mostly overlooked. Does recent receptivity from the Food and Drug Administration make ChemoCentryx a good stock to buy now, or is there another heartbreak on the horizon?
